

FORM PTO 1449 (modified)

Atty. Docket No.
X-10242

Serial No.

09/209,799

INFORMATION DISCLOSURE CITATION
IN AN APPLICATIONApplicant
Ronald N. Hermeling, et al.Filing Date
12/11/98

Group

Jd135 U.S. PTO
09/209799

12/11/98

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
FH ✓	AA	5,120,712	6/9/92	Habener, J.	514	12	
FM ✓	AB	5,118,666	6/2/92	Habener, J.	514	12	
FM ✓	AC	5,545,618	8/13/96	Buckley, D.	514	12	
FM ✓	AD	5,705,483	1/6/98	Galloway, J.	514	12	
FH ✓	AE	5,512,549	4/30/96	Chen, V.	514	12	
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Translation	
							yes	no
FM ✓	BA	EPO 619322A3	3/13/96	EPO				
FM ✓	BB	WO 95/05848	3/2/95	PCT				
FM ✓	BC	WO 93/25579	12/23/95	PCT				
FM ✓	BD	WO 98/19698	5/14/98	PCT				
FM ✓	BE	WO 98/08871	3/5/98	PCT				
FM ✓	BF	WO 97/15296	5/1/97	PCT				
FM ✓	BG	WO 96/20005	7/4/96	PCT				
FM ✓	BH	WO 98/20895	5/22/98	PCT				

EXAMINER

F. Moëzié

DATE CONSIDERED

1/5/00

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO 1449 (modified)		Atty. Docket No. X-10242	Serial No. 09209799
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Ronald N. Hermeling, et al.	
		Filing Date	Group 1653
Examiner Initial FM OTHER DOCUMENTS (Including Author, Journal, Date)			
FM ✓	CA	Komatsu, R., et al., <i>Diabetes</i> , <u>38</u> :902-905 (1989).	
FM ✓	CB	Orskov, C., et al., <i>J. Biol. Chem.</i> , <u>264</u> (22):12826-12829 (1989).	
FM ✓	CC	Majsov, S., <i>Int. J. Peptide Protein Res.</i> , <u>40</u> :33-343 (1989).	
FM ✓	CD	Holz, G.G., et al., <i>Nature</i> , <u>361</u> :362-365 (1993).	
FM ✓	CE	Orskov, C., <i>Diabetologia</i> , <u>35</u> :701-711 (1992).	
FM ✓	CF	Mentlein, R., et al., <i>Eur. J. Biochem.</i> , <u>214</u> :829-835 (1993).	
FM ✓	CG	Nauck, M.A., et al., <i>J. Clin. Invest.</i> , <u>91</u> :301-307 (1993).	
FM ✓	CH	Nauck, M.A., et al., <i>Diabetologia</i> , <u>36</u> :741-744 (1993).	
FM ✓	CI	Gutniak, M., et al., <i>N. E. J. Med.</i> , <u>326</u> (20):1316-1322, (1992).	
FM ✓	CJ	Thorens, B., et al., <i>Diabetes</i> , <u>42</u> :1219-1225 (1993).	
FM ✓	CK	Suzuki, S., et al., <i>Endocrinology</i> , <u>125</u> , 3109-3114, (1990).	
FM ✓	CL	Ananthanancayanan, V.V., et al., <i>Mol. Biol. Cell</i> (Supp) <u>3</u> , 250A, #1452 (1992).	
FM ✓	CM	Epand, R.M., <i>Mol. Pharmacol.</i> , <u>22</u> :105-108 (1982).	
FM ✓	CN	Kim, Y et al., <i>Pharm. Res.</i> , <u>12</u> :1664-1670 (1995).	
FM ✓	CO	Naslund, E. et al., <i>Drug News Perspect</i> , <u>11</u> :92-97 (1998).	
FM ✓	CP	Naslund, E. et al., <i>Am. J. Clin. Nutr.</i> , <u>68</u> :525-530 (1998).	
FM ✓	CQ	Flint, A. et al., <i>J. Clin. Invest.</i> , <u>101</u> :515-520 (1998).	
EXAMINER F. Maegle		DATE CONSIDERED 1/5/00	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			